- Home
- POR vs TGTX Comparison
POR vs TGTX Comparison
Compare POR & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POR
- TGTX
- Stock Information
- Founded
- POR 1889
- TGTX 1993
- Country
- POR United States
- TGTX United States
- Employees
- POR N/A
- TGTX N/A
- Industry
- POR Electric Utilities: Central
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- POR Utilities
- TGTX Health Care
- Exchange
- POR Nasdaq
- TGTX Nasdaq
- Market Cap
- POR 4.9B
- TGTX 5.4B
- IPO Year
- POR N/A
- TGTX 1995
- Fundamental
- Price
- POR $44.62
- TGTX $33.19
- Analyst Decision
- POR Buy
- TGTX Strong Buy
- Analyst Count
- POR 9
- TGTX 6
- Target Price
- POR $49.13
- TGTX $40.67
- AVG Volume (30 Days)
- POR 869.8K
- TGTX 2.3M
- Earning Date
- POR 10-25-2024
- TGTX 11-04-2024
- Dividend Yield
- POR 4.49%
- TGTX N/A
- EPS Growth
- POR 51.49
- TGTX N/A
- EPS
- POR 3.35
- TGTX N/A
- Revenue
- POR $3,341,000,000.00
- TGTX $264,790,000.00
- Revenue This Year
- POR $9.10
- TGTX $43.74
- Revenue Next Year
- POR $5.71
- TGTX $64.30
- P/E Ratio
- POR $13.28
- TGTX N/A
- Revenue Growth
- POR 15.81
- TGTX 39.53
- 52 Week Low
- POR $39.14
- TGTX $12.84
- 52 Week High
- POR $49.85
- TGTX $36.84
- Technical
- Relative Strength Index (RSI)
- POR 32.48
- TGTX 55.20
- Support Level
- POR $43.95
- TGTX $30.41
- Resistance Level
- POR $48.40
- TGTX $35.03
- Average True Range (ATR)
- POR 0.68
- TGTX 1.55
- MACD
- POR -0.23
- TGTX -0.33
- Stochastic Oscillator
- POR 20.41
- TGTX 51.78
About POR Portland General Electric Co
Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.5 gigawatts of gas, coal, wind, and hydro generation.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.